Intellia Therapeutics Inc. NTLA
$14.46
▼ -1.94% 24H
About
Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside t…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees377
TickerNTLA
Statistics
Market Cap$1.74B
Revenue (TTM)$67.7M
Net Income-$412.7M
Net Margin-609.9%
EPS$-3.81
P/E-3.24
P/S26.11
P/B2.40
EV/EBITDA-3.48
ROE-56.3%
Dividend Yield—
Price$14.46
Data: Twelve Data · Revenue = mcap / P/S